IRIS
MASSA, FEDERICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.007
Totale 3.007
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 3.007
Totale 3.007
Salva come PNG Salva come JPEG
Città #
Genova 1.533
Genoa 687
Rapallo 474
Vado Ligure 284
Bordighera 29
Totale 3.007
Salva come PNG Salva come JPEG
Nome #
Head-to-Head Comparison among Semi-Quantification Tools of Brain FDG-PET to Aid the Diagnosis of Prodromal Alzheimer's Disease 121
Prediction of cognitive worsening in de novo Parkinson's disease: Clinical use of biomarkers 118
Striatal dopamine transporter SPECT quantification: head-to-head comparison between two three-dimensional automatic tools 112
Spinocerebellar ataxia 17: full phenotype in a 41 CAG/CAA repeats carrier. 111
Accuracy and generalization capability of an automatic method for the detection of typical brain hypometabolism in prodromal Alzheimer disease 110
Could arterial spin labelling perfusion imaging uncover the invisible in N-methyl-d-aspartate receptor encephalitis? 100
Serum neurofilament light chain rate of change in Alzheimer's disease: potentials applications and notes of caution 97
Neuroimaging findings and clinical trajectories of Lewy body disease in patients with MCI 91
The fate of patients with REM sleep behavior disorder and Mild Cognitive Impairment 85
Added value of semiquantitative analysis of brain FDG-PET for the differentiation between MCI-Lewy bodies and MCI due to Alzheimer’s disease 83
Increased incidence of axonal Guillain-Barré syndrome in La Spezia area of Italy: A 13-year follow-up study 81
Getting the high school diploma with only one hemisphere: a case report 78
Brain Resources: How Semantic Cueing Works in Mild Cognitive Impairment due to Alzheimer’s Disease (MCI-AD) 77
Reciprocal Incremental Value of 18F-FDG-PET and Cerebrospinal Fluid Biomarkers in Mild Cognitive Impairment Patients Suspected for Alzheimer's Disease and Inconclusive First Biomarker 76
N-methyl-D-aspartate receptor antibody-related pathologies and pre-existent mental state disorders 74
Metabolic correlates of reserve and resilience in MCI due to Alzheimer's Disease (AD) Rik Ossenkoppele 72
Clinical and MRI Predictors of Conversion From Mild Behavioural Impairment to Dementia 70
Importance of intensive and prolonged rehabilitative treatment on the Guillain-Barrè syndrome long-term outcome: a retrospective study 70
Neuroimaging Findings in Mild Cognitive Impairment 70
Anatomical and neurochemical bases of theory of mind in de novo Parkinson's Disease 69
The role of anterior prefrontal cortex in prospective memory: an exploratory FDG-PET study in early Alzheimer's disease 67
Utility of quantitative EEG in early Lewy body disease 65
Epilepsy in Neurodegenerative Dementias: A Clinical, Epidemiological, and EEG Study 64
Bendamustine-rituximab (BR) combined therapy for treatment of immuno-mediated neuropathies associated with hematologic malignancy. 63
A case series of parainfectious Guillain-Barré syndrome linked to influenza A (H1N1) virus infection 63
REMeDio: a proof-of-concept neuroprotection study for prodromal synucleinopathies 55
Brain metabolic correlates of persistent olfactory dysfunction after sars-cov2 infection 53
Clinical utility and research frontiers of neuroimaging in movement disorders 51
Outcomes after single-cycle rituximab monotherapy in patients with anti-MAG polyneuropathy: A bi-center experience with an average follow-up of 11 years 51
Cuneus/precuneus as a central hub for brain functional connectivity of mild cognitive impairment in idiopathic REM sleep behavior patients 47
Polysomnographic correlates of sleep disturbances in de novo, drug naïve Parkinson's Disease 47
Subgroup comparison according to clinical phenotype and serostatus in autoimmune encephalitis: a multicenter retrospective study 46
Stratification Tools for Disease-Modifying Trials in Prodromal Synucleinopathy 45
Abnormal sweating and “skin flushing” as possible predictive factor for treatment related fluctuations in Guillain-Barré syndrome: a case series and a review of the literature 44
null 41
FDG PET Unveils the Course of Paraneoplastic Cerebellar Degeneration: A Semiquantitative Analysis 40
The Role of Hub and Spoke Regions in Theory of Mind in Early Alzheimer’s Disease and Frontotemporal Dementia 40
The Free and Cued Selective Reminding Test: Discriminative Values in a Naturalistic Cohort 39
Tracking the progression of Alzheimer's disease: Insights from metabolic patterns of SOMI stages 36
Dopaminergic and Serotonergic Degeneration and Cortical [18 F]Fluorodeoxyglucose Positron Emission Tomography in De Novo Parkinson's Disease 36
Neurological long-COVID in the outpatient clinic: Two subtypes, two courses 35
Different z-score cut-offs for striatal binding ratio (SBR) of DaT SPECT are needed to support the diagnosis of Parkinson’s Disease (PD) and dementia with Lewy bodies (DLB) 28
Case Report: Post-COVID-19 Vaccine Recurrence of Guillain-Barré Syndrome Following an Antecedent Parainfectious COVID-19-Related GBS 28
Discrepancy Between Patient and Caregiver Estimate of Apathy Predicts Dementia in Patients with Amnestic Mild Cognitive Impairment 27
Integrating cerebrospinal fluid and [18F]-fluorodeoxyglucose positron emission tomography to diagnose Alzheimer's disease and research its pathophysiological substrates 27
Cerebrospinal fluid NPTX2 changes and relationship with regional brain metabolism metrics across mild cognitive impairment due to Alzheimer's disease 25
Alzheimer's disease (AD) co-pathology in dementia with Lewy bodies (DLB): implications in the disease modification era 23
Sex differences in neuroimaging biomarkers in healthy subjects and dementia 19
A case of Huntington disease-like 2 in a patient of African ancestry: the everlasting support of clinical examination in the molecular era 18
Compressed sensing (CS) MP2RAGE versus standard MPRAGE: A comparison of derived brain volume measurements 18
Intravenous immunoglobulin bridging to rituximab in NMDAR encephalitis patients non-responders to first-line treatments 15
Cognitive and Brain Metabolism Profiles of Mild Cognitive Impairment in Prodromal Alpha-Synucleinopathy 15
Derivation and Validation of a Phenoconversion-Related Pattern in Idiopathic Rapid Eye Movement Behavior Disorder 13
Validation of the REM behaviour disorder phenoconversion-related pattern in an independent cohort 13
The Role of Monoaminergic Tones and Brain Metabolism in Cognition in~de~novo Parkinson's Disease 13
Exploring the brain metabolic correlates of process-specific CSF biomarkers in patients with MCI due to Alzheimer's disease: preliminary data 11
COVID-19-associated serum and cerebrospinal fluid cytokines in post- versus para-infectious SARS-CoV-2-related Guillain–Barré syndrome 10
Incident anti-LGI1 autoimmune encephalitis during dementia with Lewy bodies: when Occam razor is a double-edged sword 9
CSF Synaptic Biomarkers in AT(N)-Based Subgroups of Lewy Body Disease 8
Machine learning based analysis of FDG-PET image data for the diagnosis of neurodegenerative diseases 8
Presynaptic Dopaminergic Imaging Characterizes Patients with REM Sleep Behavior Disorder Due to Synucleinopathy 8
Cerebrospinal fluid β-synuclein as a synaptic biomarker for preclinical Alzheimer's disease 8
European consensus for the diagnosis of MCI and mild dementia: Preparatory phase 8
Right posterior hypometabolism in Pisa syndrome of Parkinson's disease: A key to explain body schema perception deficit? 8
18F-FDG-PET/CT (FDG-PET) in Neurodegenerative Disease 7
Diagnostic performance of molecular imaging methods in predicting the progression from mild cognitive impairment to dementia: an updated systematic review 5
FDG-PET and ASL MRI identify largely overlapping hypermetabolic and hyperperfusion changes in limbic autoimmune encephalitis 3
Editorial: CSF and blood biomarkers in COVID-19 and other neuroinfectious diseases 3
Autoimmune encephalitis: what the radiologist needs to know 3
Specific Cerebrospinal Fluid SerpinA1 Isoform Pattern in Alzheimer’s Disease 3
Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration 3
Clinical versus biomarker-based diagnosis of neurocognitive disorders – Authors' reply 3
Relationship between default mode network and resting-state electroencephalographic alpha rhythms in cognitively unimpaired seniors and patients with dementia due to alzheimer’s disease 3
Case 4: Parkinson’s Disease with Onset as Mild Cognitive Impairment (MCI) 3
Diagnostic and prognostic value of dual-point amyloid PET in Alzheimer’s disease (AD) mimickers 3
Ma2 antibody-associated limbic encephalitis: The early etiology treatment may modify the disease clinical trajectory 3
Sex differences in brain atrophy in dementia with Lewy bodies 2
Clinical and diagnostic implications of Alzheimer’s disease copathology in Lewy body disease 2
Limbic Network Derangement Mediates Unawareness of Apathy in Mild Cognitive Impairment due to Alzheimer’s Disease: Clues from [18F]FDG PET Voxel-Wise Analysis 2
European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders 2
Toward Quantitative Neurology: Sensors to Assess Motor Deficits in Dementia 2
Resting state electroencephalographic alpha rhythms are sensitive to Alzheimer's disease mild cognitive impairment progression at a 6-month follow-up 2
Totale 3.207
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.182
article - articoli 14.422
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 619
Totale 30.223
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020514 0 0 0 32 45 61 59 70 74 100 55 18
2020/2021514 21 46 22 92 69 55 44 31 30 55 21 28
2021/2022495 28 5 8 35 29 40 23 92 45 84 30 76
2022/2023561 40 60 8 51 70 70 7 49 85 22 84 15
2023/2024613 47 47 13 94 49 100 44 46 24 26 34 89
2024/2025371 103 116 65 87 0 0 0 0 0 0 0 0
Totale 3.207